NAS:MRTX (USA) Also Trade In: Germany

Mirati Therapeutics Inc $ 232.54 7.08 (3.14%)

Volume:
202,849
Avg Vol (1m):
533,058
Market Cap $:
11.69 Bil
Enterprise Value $:
11.11 Bil
P/E (TTM):
0.00
P/B:
18.91
Warning! GuruFocus has detected 2 Severe warning signs with MRTX. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 10Y (-%)

Mirati Therapeutics Inc News and Headlines -

GuruFocus Articles Total 9
  • 1

Company's drug for gene defects seems to be more effective than similar treatment from Amgen

Promising results from a study of its cancer drug pushed Mirati Therapeutics Inc. (MRTX) to an all-time high Monday. Shares of the San Diego-based biotech hit more than $210 and are at about $205 on Tuesday. Meanwhile, the stock of rival Amgen Inc. (AMGN) slid to a four-month low before closing at just under $225.

Mirati and Amgen are in a race to find which of the companies' drugs work best in treating defects in the gene called KRAS. KRAS mutations are found in many lung, colorectal and pancreatic cancers, and the lack of an approved therapy designed to attack

63 Views    Barry Cohen    2020-10-27 18:11
Fund reveals 1st-quarter trades

When it released its portfolio for the first quarter of the year last week, the Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) disclosed three new holdings.

Managed by Jason Kritzer and Samantha Pandolfi, the fund, which is part of Boston-based Eaton Vance, invests heavily in the health care space. The portfolio managers look around the world for securities that are not only reasonably priced, but which they believe will grow in value over time.

Keeping these criteria in mind, the fund established positions in Mirati Therapeutics Inc. (MRTX), Deciphera Pharmaceuticals Inc. (DCPH) and JMDC Inc. (TSE:4483)

252 Views    Sydnee Gatewood    2020-05-04 16:36
Company's shares up 70% just days after public offering

The share price of a clinical-stage oncology company that went public just last week has climbed more than 70% on hopes that it can develop drugs to transform the way cancer is treated.

Redwood City, California-based Revolution Medicines Inc. (RVMD) sold 14 million shares at $17 each on Feb. 13, 2020, raising a total of $238 million (more than twice its original goal). At close on Feb. 18, shares were trading at just over $29.

The six-year-old company will use the funds to push along drug candidates that block certain proteins that cause cancer to grow and thrive. The pharmaceutical

105 Views    Barry Cohen    2020-02-19 15:35
Although still in early testing, the company's therapy could be a game changer for patients and investors

Amgen Inc. (AMGN) has accomplished something cancer researchers have failed to do for decades. That is, develop a potentially breakthrough treatment for one of the most well-known genetic causes of cancer. It could be a game changer for treating certain types of tumors, benefiting patients and rewarding the company and its shareholders.

The company presented results of an early-stage trial for the drug AMG 510 at the American Society of Clinical Oncology meeting on June 3 in Chicago. Over the following two days, Amgen's shares climbed more than $4. Investors must have anticipated the company was going to present good

524 Views    Barry Cohen    2019-06-04 21:46
TCR2 Therapeutics, Mirati Therapeutics among stocks bought and sold by insiders

The GuruFocus All-in-One Screener can be used to find insider trades from the past week. Under the Insiders tab, change the settings for All Insider Buying to “$200,000+,” the duration to “February 2019” and All Insider Sales to “$5,000,000+.”

According to these filters, the following are trades from company insiders this week.

Part owners MPM BioVentures 2014 L.P., the Oncology Impact Fund (Cayman), Upnorth Investment Ltd and directors Morana Jovan-Embiricos and Ansbert Gadicke, bought a combined 4,319,999 shares of TCR2 Therapeutics Inc. (TCRR) for an average price of $15 per share on Feb.

106 Views    Tiziano Frateschi    2019-02-22 17:40
Largest insider trades of the week

The GuruFocus All-in-One Screener can be used to find insider trades from the past week. Under the Insiders tab, change the settings for All Insider Buying to “$200,000+,” the duration to “November 2017” and All Insider Sales to “$5,000,000+.”

According to the above filters, the following are trades from company insiders this week.

venBio Select Advisor LLC, 10% owner of Mirati Therapeutics Inc. (MRTX), bought 650,000 shares for $13.00 per share on Nov. 16. Since then, the stock price has risen to $19.00.

The biotechnology company has a market cap of $480.73 million and an enterprise value of

137 Views    Tiziano Frateschi    2017-11-17 22:24
Largest insider trades of the week

The GuruFocus All-in-One Screener can be used to find insider trades from the past week. Under the Insiders tab, change the settings for All Insider Buying to “$200,000+,” the duration to “January 2017” and All Insider Sales to “$5,000,000+.”

According to the above filters, the following are trades from company insiders this week.

Michael G. Van de Ven, director of Comerica Inc. (CMA), bought 5,000 shares for $69.14 per share on Jan 25. Since then, the stock price has risen 0.6% to $69.58.

The company has an institutional ownership of 82.56% and insider ownership of 2.79%. It is a

129 Views    Tiziano Frateschi    2017-01-27 20:08
Company's president buys 20,000 shares

Mirati Therapeutics Inc. (MRTX) President and CEO Charles M. Baum bought 20,000 shares on June 14 at an average price of $7.05 per share. The total transaction amount was $141,000.

Mirati Therapeutics has a market cap of $140.370 million; its shares were traded around $7.05.

Mirati Therapeutics' stock price has decreased from its initial price in 2009 of around $15 per share and also from its peak of a little above $45 per share in 2015.

444219277.png

Mirati Therapeutics has been working on several programs such as MGCD265, MGCD516Â and Mocetinostat. The company reports that its

1050 Views    alicet236    2016-06-16 22:12
Sysco among significant buys, Bruker among biggest sells

The All-in-One Screener can be used to find insider buys and sells over the last week by clicking on the Insiders tab and changing the settings for All Insider Buying to “$1,000,000+” and duration to "May 2016” and “May 2016.”

According to the above filters, the following are recent buys and sells from company insiders in the past week.

Kwok Fong Wong, director of BIO-key International Inc. (BKYI), bought 565,712 shares in the company at 23 cents per share on June 7. Since then, the price of the stock has risen by 4.3% to 24 cents.

The company

2197 Views    Tiziano Frateschi    2016-06-10 20:00

Headlines Total 30
  • 1

2020-11-05 $ 234.68 (6.17%)
6:05pm
2020-10-30 $ 217.14 (-1.29%)
7:39am
2020-10-27 $ 209.16 (6.35%)
1:11pm
2020-10-26 $ 196.68 (9.15%)
11:32am
11:31am
2020-10-12 $ 184.5 (0.65%)
3:48am
2020-09-05
10:32am
2020-07-27 $ 120.39 (3.3%)
11:31am
2020-06-16 $ 107.75 (0.54%)
5:38pm
2020-06-06
10:31am
2020-05-29 $ 99.19 (-3.7%)
1:32pm
2020-05-13 $ 104.59 (-3.55%)
4:15pm
2020-05-08 $ 93.4 (1.36%)
7:00pm
2020-05-04 $ 91.37 (10.34%)
11:36am
2020-04-27 $ 90 (5.47%)
11:32am
2020-04-21 $ 85.62 (-10.23%)
2:10pm
7:15am
2020-04-20 $ 95.38 (5.16%)
7:00am
2020-03-25 $ 82.81 (1.66%)
5:38pm
2020-03-17 $ 70.13 (-13.68%)
8:38pm
2020-03-06 $ 89.18 (-6.99%)
8:38pm
2020-03-04 $ 91.43 (-3.99%)
8:38pm
2020-02-18 $ 92.17 (%)
8:38pm
2019-12-27 $ 127.41 (0.37%)
6:15pm
2019-12-19 $ 112.42 (-3.46%)
8:38pm
2019-12-17 $ 116.45 (3.31%)
5:38pm
2019-12-12 $ 106.12 (0.36%)
5:38pm
2019-11-22 $ 87.03 (-2.25%)
5:38pm
2018-12-04 $ 38.7 (-4.77%)
7:01am
2016-06-16 $ 7.05 (0.57%)
5:12pm
Total 30
  • 1